22 January 2024
22 January 2024
The approval comes after the company received an accelerated approval in April 2019.
The layoffs will free cash resources that will extend financial runways and focus pipeline developmental efforts.
CIMERLI is a biosimilar to the reference product LUCENTIS, indicated to treat retinal diseases.
Kyverna is carrying out two trials of KYV-101 in lupus nephritis patients.
By 2030, the anti-obesity medicines market could grow to $30bn for the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), according to GlobalData’s Epidemiology and Market Size database.
The latest final draft guidance reverses a previous decision by the institute.
Ikena has also paused exploratory research and discovery in addition to workforce reduction, which will occur over Q1 this year.
Information gathered from the study will guide an two-week mission scheduled for launch in March.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
